Get the Full Story, Without the Noise.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Memorial Day
Cannes Film Festival
Artificial Intelligence
Harvard
Regulation
Social Media
Natural Disasters
Work
Education
Donald Trump
Stock Markets
Baseball
Published • loading... • Updated

Cereno aligns with FDA on CS1 drug development path for PAH

Summary by Pulmonary Hypertension News
Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy candidate CS1.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Pulmonary Hypertension NewsPulmonary Hypertension News

Cereno aligns with FDA on CS1 drug development path for PAH

Cereno Scientific reported a successful meeting with the FDA on the design of a future clinical trial for its PAH therapy candidate CS1.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Pulmonary Hypertension News broke the news in on Wednesday, April 30, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Maryland

Maryland

News
For You
SearchBlindspotLocal